HB 3799
Creates a method by which a health care practitioner may offer to treat a patient who has a terminal disease or severe chronic disease with an investigational product not approved by the United States Food and Drug Administration.
Jurisdiction
Oregon
Session
2025 Regular Session
At the request of
(at the request of Dr. John Kitzhaber, M.D.)
Committee
Behavioral Health and Health Care
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill allows doctors to offer investigational treatments to patients with terminal or severe chronic diseases, even if those treatments haven't been approved by the FDA. It provides protections for healthcare providers involved, including a waiver of liability, and requires patients to be fully informed about the risks and costs of the treatment. The bill also establishes procedures for referring patients to consulting physicians and requires insurers to not reimburse costs associated with these treatments.
Key provisions
- Allows doctors to offer investigational treatments to patients with terminal or severe chronic diseases.
- Provides liability protections for healthcare practitioners, facilities, and manufacturers involved in offering these treatments.
- Requires patients to waive liability before receiving the treatment.
- Mandates that patients be fully informed about the investigational nature of the treatment, potential risks, and costs.
- Establishes a referral process to a consulting physician for diagnosis and prognosis confirmation.
- Requires insurers to not reimburse costs associated with the treatment.
- Defines eligibility criteria for patients, including residency requirements.
- Specifies requirements for witness signatures on consent forms.
Who is affected
- Patients with terminal or severe chronic diseases
- Healthcare practitioners (doctors, nurses, etc.)
- Healthcare facilities
- Pharmaceutical manufacturers and distributors
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsor
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yours